AstraZeneca’s Farxiga cuts death risk in heart failure patients – study
AstraZeneca’s Farxiga cuts death risk in heart failure patients – study By Natalie Grover LONDON, Aug 27 (Reuters) – AstraZeneca’s (AZN.L)
AstraZeneca’s Farxiga cuts death risk in heart failure patients – study By Natalie Grover LONDON, Aug 27 (Reuters) – AstraZeneca’s (AZN.L)
Editor’s Note: We asked authors of Original Investigations to provide short plain-language summaries that would briefly summarize what inspired
Apr 06, 2022 By Heather McKenzie BioSpace Often media-elusive, Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump
Summary We recap the top pearls from 2021, including celiac disease, kidney stones, SGLT2 inhibitors for weight loss & HFpEF, smoking
Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication of data from the
SGLT2 inhibitors for CKD, Turmeric for knee pain and Honey for URTI. Summary Time for spooky cakes with a side of candy corn. We discuss
The FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Boehringer Ingelheim and Eli Lilly
Brendon Neuen @brendonneuen Brendon Neuen is an academic nephrology registrar at Royal North Shore Hospital and an NHMRC Postgraduate Scholar at The
Quick confession: I have never read or seen anything about Harry Potter in my life. It isn’t because I am opposed to the Rowling machine. I